MX2020013083A - Compuestos de pirazolopirimidina como antagonistas del receptor de adenosina. - Google Patents

Compuestos de pirazolopirimidina como antagonistas del receptor de adenosina.

Info

Publication number
MX2020013083A
MX2020013083A MX2020013083A MX2020013083A MX2020013083A MX 2020013083 A MX2020013083 A MX 2020013083A MX 2020013083 A MX2020013083 A MX 2020013083A MX 2020013083 A MX2020013083 A MX 2020013083A MX 2020013083 A MX2020013083 A MX 2020013083A
Authority
MX
Mexico
Prior art keywords
sub
alkyl
optionally substituted
halogens
independently selected
Prior art date
Application number
MX2020013083A
Other languages
English (en)
Inventor
Andrew Simon Bell
Adrian Michael Schreyer
Stéphanie Versluys
Original Assignee
Exscientia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exscientia Ltd filed Critical Exscientia Ltd
Publication of MX2020013083A publication Critical patent/MX2020013083A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Abstract

La invención proporciona un compuesto de fórmula (I), o un éster, amida, carbamato, solvato o sal de este farmacéuticamente aceptable, incluyendo una sal de tal éster, amida o carbamato, (ver Fórmula) en donde R1 es un fenilo opcionalmente sustituido, o un heterociclo aromático de 5 o 6 miembros opcionalmente sustituido que comprende 1, 2 o 3 heteroátomos seleccionados independientemente del grupo que consiste en N, S y O, en donde dicho fenilo está opcionalmente sustituido con 1, 2 o 3 sustituyentes, cada sustituyente seleccionado independientemente del grupo que consiste en halógeno, OH, alquilo C1-8, alquilo C1-8 sustituido con 1, 2 o 3 halógenos o grupos OH, alquilo OC1-8 y alquilo OC1-8 sustituido con 1, 2 o 3 halógenos o grupos OH, y en donde dicho heterociclo aromático de 5 o 6 miembros está opcionalmente sustituido con 1, 2 o 3 sustituyentes, cada sustituyente seleccionado independientemente del grupo que consiste en halógeno, OH, alquilo C1-8, alquilo OC1-8 sustituido con 1, 2 o 3 halógenos o grupos OH, alquilo OC1-8 y alquilo OC1-8 sustituido con 1, 2 o 3 halógenos o grupos OH; y R2 es un heterociclo aromático de 5 o 6 miembros opcionalmente sustituido que comprende 2 o 3 heteroátomos seleccionados independientemente del grupo que consiste en N, S y O, en donde dicho heterociclo aromático de 5 o 6 miembros está opcionalmente sustituido con 1, 2 o 3 sustituyentes, cada sustituyente seleccionado independientemente del grupo que consiste en alquilo C1-3 y alquilo C1-3 sustituido con 1, 2 o 3 halógenos. La invención también proporciona composiciones farmacéuticas que comprenden un compuesto de fórmula (I) y el uso de compuestos de fórmula (I) como medicamentos, en particular en el tratamiento del cáncer.
MX2020013083A 2018-06-04 2019-06-04 Compuestos de pirazolopirimidina como antagonistas del receptor de adenosina. MX2020013083A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18290061 2018-06-04
PCT/EP2019/064450 WO2019233994A1 (en) 2018-06-04 2019-06-04 Pyrazolopyrimidine compounds as adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
MX2020013083A true MX2020013083A (es) 2021-05-27

Family

ID=62750904

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013083A MX2020013083A (es) 2018-06-04 2019-06-04 Compuestos de pirazolopirimidina como antagonistas del receptor de adenosina.

Country Status (10)

Country Link
US (2) US11786528B2 (es)
EP (1) EP3802540A1 (es)
JP (1) JP2021526150A (es)
KR (1) KR20210033444A (es)
CN (1) CN112533923A (es)
AU (2) AU2019282098B2 (es)
BR (1) BR112020024700A2 (es)
CA (1) CA3100923A1 (es)
MX (1) MX2020013083A (es)
WO (1) WO2019233994A1 (es)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU716633B2 (en) * 1996-06-06 2000-03-02 Otsuka Pharmaceutical Factory, Inc. Amide derivatives
BR0115847A (pt) * 2000-12-01 2004-02-25 Osi Pharm Inc Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
AU2002315389A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
SE0203825D0 (sv) 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US20100273776A1 (en) 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
WO2008141385A1 (en) 2007-05-21 2008-11-27 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
MX2009014203A (es) 2007-06-26 2010-01-28 Sanofi Aventis Una sintesis de 2h-indazoles catalizada por un metal de transicion.
BRPI0820342A2 (pt) 2007-11-07 2015-05-26 Foldrx Pharmaceuticals Inc Modulação de tráfego de proteína
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
EA023254B1 (ru) 2010-05-27 2016-05-31 Мерк Шарп Энд Домэ Корп. Активаторы растворимой гуанилатциклазы
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
WO2014126580A1 (en) 2013-02-15 2014-08-21 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9695166B2 (en) 2014-05-05 2017-07-04 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
WO2016004272A1 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016011394A1 (en) 2014-07-18 2016-01-21 The General Hospital Corporation Imaging agents for neural flux
JP6663493B2 (ja) 2015-08-11 2020-03-11 ノバルティス アーゲー がんの処置に使用するための５−ブロモ−２，６−ジ−（１ｈ−ピラゾール−１−イル）ピリミジン−４−アミン
WO2017112917A1 (en) 2015-12-24 2017-06-29 Corvus Pharmaceuticals, Inc. Methods of treating cancer
US11760752B2 (en) 2019-03-21 2023-09-19 University Of Maryland, Baltimore Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors
WO2020243457A1 (en) 2019-05-29 2020-12-03 Viogen Biosciences, Llc Compounds and therapeutic uses thereof
CN112608318B (zh) 2019-12-16 2023-09-08 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其用途
WO2021121397A1 (zh) 2019-12-19 2021-06-24 首药控股(北京)股份有限公司 取代的炔基杂环化合物
EP4259619A1 (en) 2020-12-08 2023-10-18 Disarm Therapeutics, Inc. Benzopyrazole inhibitors of sarm1
CN117580836A (zh) 2021-06-24 2024-02-20 四川汇宇制药股份有限公司 一种嘧啶并环结构衍生物及其用途

Also Published As

Publication number Publication date
CN112533923A (zh) 2021-03-19
EP3802540A1 (en) 2021-04-14
JP2021526150A (ja) 2021-09-30
BR112020024700A2 (pt) 2021-03-02
CA3100923A1 (en) 2019-12-12
US20240108624A1 (en) 2024-04-04
US11786528B2 (en) 2023-10-17
WO2019233994A1 (en) 2019-12-12
KR20210033444A (ko) 2021-03-26
US20210251995A1 (en) 2021-08-19
AU2019282098B2 (en) 2023-12-14
AU2024200136A1 (en) 2024-01-25
AU2019282098A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12020551305A1 (en) Pharmaceutical Compounds
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
RU2495044C2 (ru) Ингибиторы активности протеинтирозинкиназы
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MY189118A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
JP2017528524A5 (es)
RU2017105781A (ru) Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение
GEP20227359B (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
CL2020000363A1 (es) Inhibidores macrocíclicos de mcl-1 y métodos de uso.
EA200701780A1 (ru) Противоопухолевое средство
WO2019165043A3 (en) Indane-amines as pd-l1 antagonists
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
CR20200418A (es) Inhibidores de orginasa y sus mètodos de uso antecedentes
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
AR109952A1 (es) Derivados de fenilamina 4-sustituidos y su uso para proteger cultivos al combatir microorganismos fitopatogénicos indeseados
CY1107677T1 (el) Παραγωγα της 1-[indol-3-yl)carbonyl]piperazine
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
AR108906A1 (es) Heterociclos de biarilmetilo
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
RU2016141405A (ru) (5,6-дигидро)пиримидо[4,5-е]индолизины
RU2017124423A (ru) Соединения дигидропиримидин-2-она и их медицинское применение
AR054707A1 (es) Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento